Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours

Next Previous
Trial Profile

Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Idronoxil (Primary) ; Carboplatin
  • Indications Advanced breast cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms CEP-1
  • Sponsors Noxopharm

    • Most Recent Events

    • 07 Mar 2018 Results for patients receiving 800mg NOX66 presented at the 16th International Congress on Targeted Anticancer Therapies
    • 06 Mar 2018 Results (n = 15) presented in a Noxopharm media release.
    • 06 Mar 2018 According to a Noxopharm media release, data from this trial were presented at the 2018 ESMO International Congress on Targeted Anticancer Therapies. The last patient is due to complete treatment in April 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top